source
- Celldex drops eczema antibody barzolvolimab after Phase 2 failureCelldex Therapeutics said it is ending development of its monoclonal antibody barzolvolimab as a treatment for eczema. The Phase 2 study did not show a statistically significant reduction in itchi…
- Teva appoints interim R&D head as Eric Hughes departsTeva announced that its global research and development leader and chief medical officer, Eric Hughes, has left the company. Hughes, who joined Teva in 2022 after a senior role at Vertex, will be s…